---
layout: default
title: Warfarin
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 34
evidence_level: L5
indication_count: 3
---

# Warfarin
{: .fs-9 }

è­‰æ“šç­‰ç´š: **L5** | é æ¸¬é©æ‡‰ç—‡: **3** å€‹
{: .fs-6 .fw-300 }

---

## ç›®éŒ„
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pharmacist Notes â€” Warfarin è€è—¥æ–°ç”¨

---

## âš ï¸ è³‡æ–™å®Œæ•´æ€§èˆ‡å¯ç”¨æ€§è²æ˜

**æ–‡ä»¶ç”¢å‡ºæ—¥æœŸ**ï¼š2026-02-09
**æ±ºç­–éšæ®µ**ï¼šS0ï¼ˆåˆæ­¥è©•ä¼°ï¼‰
**ç›®å‰æ±ºç­–**ï¼šHold

### æœ¬æ–‡ä»¶å¯æ”¯æŒçš„æ±ºç­–

| å¯æ”¯æŒ | ä¸å¯æ”¯æŒ |
|-------|---------|
| ç„¡ | è‡¨åºŠæ‡‰ç”¨ã€è©¦é©—è¨­è¨ˆ |

### é˜»æ–·æ€§ç¼ºå£æ‘˜è¦

| # | ç¼ºå£é …ç›® | æ¨è«–é™åˆ¶ | è§£é–æ¢ä»¶ |
|---|---------|---------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | ç„¡æ³•é€²è¡Œæ©Ÿè½‰é—œè¯æ€§åˆ†æ | éœ€æŸ¥è©¢ DrugBank API ç²å–è©³ç´° MOA è³‡è¨Š |

### ä¿å®ˆå‡è¨­æ‘˜è¦

| # | å‡è¨­ | ä¾æ“š | é™åˆ¶ | è§¸ç™¼æ¢ä»¶ |
|---|------|------|------|---------|
| ç„¡ | ç„¡ | ç„¡ | ç„¡ | ç„¡ |

---

> âš ï¸ **é‡è¦è²æ˜**
>
> 1. æœ¬æ–‡ä»¶åŒ…å«ã€Œå·²è­‰å¯¦è³‡è¨Šã€èˆ‡ã€Œå‡è¨­/æ¨è«–ã€ã€‚
> 2. å‡¡æ¨™ç¤ºç‚º **Blocking Data Gap** ä¹‹é …ç›®æœªè§£é™¤å‰ï¼Œæœ¬æ–‡ä»¶ **ä¸æä¾›**ï¼š
>    - è‡¨åºŠå»ºè­°
>    - æ’é™¤æ¢ä»¶å®šç¨¿
>    - è©¦é©—è¨­è¨ˆä¾æ“š
> 3. è‹¥å¾ŒçºŒå–å¾—æ–°è³‡æ–™ï¼Œå°‡ä¾è§£é–æ¢ä»¶æ›´æ–°é¢¨éšªåˆ†ç´šèˆ‡æ±ºç­–ã€‚

---

## 0. è³‡æ–™ä¾†æºç¨½æ ¸æ¡†ï¼ˆData Provenanceï¼‰

| è³‡æ–™ä¾†æº | ç‹€æ…‹ | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | ç­†æ•¸/å‚™è¨» | å°æ±ºç­–éšæ®µçš„å½±éŸ¿ |
|---------|------|---------|---------|----------|----------------|
| TFDA è¨±å¯è­‰ | âœ… | 2026-02-09 | {"drug": "warfarin"} | 20 | å·²ç¢ºèªä¸Šå¸‚ç‹€æ…‹ |
| TFDA ä»¿å–®ï¼ˆè­¦èª/ç¦å¿Œ/åŠ‘é‡ï¼‰ | âœ… | 2026-02-09 | {"drug": "warfarin"} | 1 | éœ€è£œå……è­¦èªèˆ‡ç¦å¿Œè³‡è¨Š |
| DDI è³‡æ–™åº« (Unified DDI) | âœ… | 2026-02-09 | {"drug": "warfarin"} | 865 | ç¢ºèªå¤šé … DDI |
| DrugBank (MOA) | âœ… | 2026-02-09 | {"drug": "warfarin"} | 1 | MOA è³‡è¨Šç¼ºå¤± |
| ClinicalTrials.gov | âœ… (ç„¡çµæœ) | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 0 | ç„¡è‡¨åºŠè©¦é©—æ”¯æŒ |
| PubMed | âœ… | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 5 | åƒ…æœ‰æœ‰é™æ–‡ç»æ”¯æŒ |

---

## 1. è—¥ç‰©å†åˆ©ç”¨ç¸½è¦½

### è—¥ç‰©åŸºæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è—¥ç‰©åç¨± | Warfarin | |
| DrugBank ID | DB00682 | |
| **åŸæ ¸å‡†é©æ‡‰ç—‡** | 1. æŠ—å‡è¡€åŠ‘ 2. è¡€ç®¡æ “å¡ã€æ‰‹è¡“å¾Œæ “å¡æ€§éœè„ˆç‚ã€è‚ºæ “å¡ç­‰ | [ä¾†æºï¼šTFDA è¨±å¯è­‰] |
| **åŸä½œç”¨æ©Ÿè½‰ (MOA)** | [Data Gap] | [ä¾†æºï¼šDrugBank] |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | å·²ä¸Šå¸‚ | TFDA |
| å¯ç”¨åŠ‘å‹ | éŒ åŠ‘ã€ç²‰åŠ‘ | |

### é æ¸¬æ–°é©æ‡‰ç—‡ç¸½è¦½

| æ’å | é æ¸¬é©æ‡‰ç—‡ | å»ºè­°åŠ‘å‹ | TxGNN åˆ†æ•¸ | è­‰æ“šç­‰ç´š | è—¥å¸«ç«‹å ´ | æ±ºç­–çµè«– | é—œéµç¼ºå£ |
|------|-----------|---------|-----------|---------|---------|---------|---------|
| 1 | heparin cofactor 2 deficiency | Pending | 99.87% | L5 | æš«ä¸å»ºè­° | Hold | æ©Ÿè½‰ä¸æ˜ |
| 2 | factor 5 excess with spontaneous thrombosis | Pending | 99.84% | L5 | æš«ä¸å»ºè­° | Hold | æ©Ÿè½‰ä¸æ˜ |
| 3 | antithrombin deficiency type 2 | Pending | 99.84% | L5 | æš«ä¸å»ºè­° | Hold | æ©Ÿè½‰ä¸æ˜ |

---

## 2. Taiwan Regulatory & Label Snapshot

### 2.1 TFDA ä¸Šå¸‚ç‹€æ…‹
- ä¸Šå¸‚ç‹€æ…‹ï¼šå·²ä¸Šå¸‚
- æ ¸å‡†é©æ‡‰ç—‡ï¼šæŠ—å‡è¡€åŠ‘ã€è¡€ç®¡æ “å¡ã€æ‰‹è¡“å¾Œæ “å¡æ€§éœè„ˆç‚ã€è‚ºæ “å¡ç­‰ [ä¾†æºï¼šTFDA è¨±å¯è­‰]
- è¨±å¯è­‰è™Ÿï¼šå…§è¡›è—¥è¼¸å­—ç¬¬002494è™Ÿã€å…§è¡›è—¥è¼¸å­—ç¬¬002938è™Ÿã€è¡›éƒ¨è—¥è¼¸å­—ç¬¬026478è™Ÿã€è¡›ç½²è—¥è£½å­—ç¬¬050068è™Ÿ

### 2.2 è¨±å¯è­‰è©³ç´°è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | æ¿ƒåº¦ | è£½é€ å»  | ä»¿å–®ç‰ˆæœ¬ |
|---------|---------|------|------|-------|---------|
| å…§è¡›è—¥è¼¸å­—ç¬¬002494è™Ÿ | æ´»ç¦å¯§éˆ‰ç‰‡ | éŒ åŠ‘ | - | é›„æ†è¡Œè‚¡ä»½æœ‰é™å…¬å¸ | - |
| å…§è¡›è—¥è¼¸å­—ç¬¬002938è™Ÿ | å®‰æ±å‘½ï¼ï¼« | éŒ åŠ‘ | - | å‰ç™¼ä¼æ¥­è‚¡ä»½æœ‰é™å…¬å¸ | - |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026478è™Ÿ | è‹¯ç”²é¦™è±†é†‡éˆ‰ç± æ™¶ | ï¼ˆç²‰ï¼‰ | - | æ–°é›™éš†ç”ŸæŠ€è‚¡ä»½æœ‰é™å…¬å¸ | - |
| è¡›ç½²è—¥è£½å­—ç¬¬050068è™Ÿ | æ¬£æœå¯§ éŒ  1 æ¯«å…‹ | éŒ åŠ‘ | 1 æ¯«å…‹ | å¥å–¬ä¿¡å…ƒé†«è—¥ç”ŸæŠ€è‚¡ä»½æœ‰é™å…¬å¸ | - |

### 2.3 ä»¿å–®é—œéµè³‡è¨Šï¼ˆæŒ‰åŠ‘å‹åˆ†åˆ—ï¼‰

#### å£æœ/å…¨èº«æ€§åŠ‘å‹

| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| ä¸»è¦è­¦èª | [Data Gap] | [ä¾†æºï¼šTFDA ä»¿å–®] |
| ç¦å¿Œç—‡ | [Data Gap] | [ä¾†æºï¼šTFDA ä»¿å–®] |
| å»ºè­°åŠ‘é‡ | [Data Gap] | [ä¾†æºï¼šTFDA ä»¿å–®] |
| å­•å“ºåˆ†ç´š | [Data Gap] | [ä¾†æºï¼šTFDA ä»¿å–®] |
| è‚åŠŸèƒ½èª¿æ•´ | [Data Gap] | [ä¾†æºï¼šTFDA ä»¿å–®] |
| è…åŠŸèƒ½èª¿æ•´ | [Data Gap] | [ä¾†æºï¼šTFDA ä»¿å–®] |
| ç‰¹æ®Šæ—ç¾¤ï¼ˆå…’ç«¥ï¼‰ | [Data Gap] | [ä¾†æºï¼šTFDA ä»¿å–®] |
| ç‰¹æ®Šæ—ç¾¤ï¼ˆè€äººï¼‰ | [Data Gap] | [ä¾†æºï¼šTFDA ä»¿å–®] |

---

## 3. Safety Profile â€” æŒ‰åŠ‘å‹åˆ†åˆ—

### 3.1 å£æœ/å…¨èº«æ€§åŠ‘å‹å®‰å…¨æ€§

#### Serious ADR

| ADR | ç™¼ç”Ÿç‡ | ä¾†æº | è™•ç½®å»ºè­° |
|-----|-------|------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

#### Common ADR

| ADR | ç™¼ç”Ÿç‡ | ä¾†æº | è™•ç½®å»ºè­° |
|-----|-------|------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

#### Stop Criteriaï¼ˆå£æœï¼‰â€” é‡åŒ–é–€æª»

| ç—‡ç‹€/å¾µè±¡ | ç­‰ç´š/æ•¸å€¼é–€æª» | è™•ç½® |
|----------|-------------|------|
| [Data Gap] | [Data Gap] | [Data Gap] |

---

## 4. Drug-Drug Interactions (DDI)

### 4.2 å£æœåŠ‘å‹ DDI

#### DDI æŸ¥æ ¸çµæœ

**æŸ¥è©¢ç‹€æ…‹**ï¼šâœ… å·²å®Œæˆ

**å·²åŸ·è¡Œçš„æŸ¥è©¢**ï¼š
1. Unified DDI è³‡æ–™åº«ï¼ˆDDInter + Guide to PHARMACOLOGYï¼‰ï¼š865 ç­†çµæœ
2. TFDA ä»¿å–®ã€Œè—¥ç‰©äº¤äº’ä½œç”¨ã€ç« ç¯€ï¼šæœªæä¾›
3. DrugBank Interactionsï¼šæœªæä¾›

**æ˜ç¢ºé™³è¿°**ï¼š
> æœ¬å ±å‘Š **å·²å®Œæˆ** DDI æ­£å¼æŸ¥æ ¸ã€‚
> ä¸Šè¿°æŸ¥è©¢çµæœ **è¶³ä»¥** æ”¯æŒã€Œå­˜åœ¨å¤šé … DDIã€çš„çµè«–ã€‚
> æ­¤ç‚º **Non-blocking Data Gap**ï¼Œå¯ç¹¼çºŒè©•ä¼°ã€‚

#### å·²çŸ¥ DDI

| ä½µç”¨è—¥å“ | åš´é‡åº¦ | æ©Ÿè½‰ | è‡¨åºŠå¾Œæœ | è™•ç½®å»ºè­° | æ›¿ä»£æ–¹æ¡ˆ |
|---------|-------|------|---------|---------|---------|
| Acetylsalicylic acid | Major | å¢åŠ å‡ºè¡€é¢¨éšª | å‡ºè¡€ | é¿å…ä½µç”¨ | ä½¿ç”¨å…¶ä»–éæŠ—å‡è¡€åŠ‘ |
| Metronidazole | Major | å¢åŠ å‡ºè¡€é¢¨éšª | å‡ºè¡€ | é¿å…ä½µç”¨ | ä½¿ç”¨å…¶ä»–æŠ—ç”Ÿç´  |
| Rabeprazole | Moderate | å½±éŸ¿è—¥ç‰©ä»£è¬ | å½±éŸ¿ç™‚æ•ˆ | ç›£æ¸¬ INR | ä½¿ç”¨å…¶ä»–åˆ¶é…¸åŠ‘ |

---

## 5. Data Gaps å®Œæ•´è¨˜éŒ„

### Data Gap #1 â€” ä½œç”¨æ©Ÿè½‰ (MOA)ï¼ˆğŸ›‘ Blockingï¼‰

| æ¬„ä½ | å…§å®¹ |
|------|------|
| **ç¼ºå£é …ç›®** | ä½œç”¨æ©Ÿè½‰ (MOA) |
| **å·²å®Œæˆæª¢ç´¢è¡Œå‹•** | |
| | â€¢ å®˜æ–¹æ¨™ç±¤/ä¸»ç®¡æ©Ÿé—œè³‡æ–™ï¼ˆTFDA/FDA/EMA/PMDAï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ æ¬Šå¨è—¥å­¸è³‡æ–™åº«ï¼ˆDDInter/Guide to PHARMACOLOGY/DrugBankï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ åŒå„•å¯©æŸ¥æ–‡ç»ï¼ˆPubMed/æœŸåˆŠï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ è©¦é©—ç™»éŒ„ï¼ˆClinicalTrials.govï¼‰ï¼šæœªæ‰¾åˆ° |
| **æª¢ç´¢çµæœ** | åƒ…äºŒæ‰‹è³‡è¨Š |
| **æ¨è«–é™åˆ¶ï¼ˆä¸èƒ½åšï¼‰** | æ©Ÿè½‰é—œè¯æ€§åˆ†æ |
| **é¢¨éšªè™•ç½®ï¼ˆæ±ºç­–ï¼‰** | Hold |
| **è§£é–æ¢ä»¶** | æŸ¥è©¢ DrugBank API ç²å–è©³ç´° MOA è³‡è¨Š |

---

## 6. å„é©æ‡‰ç—‡ç‰¹å®šè€ƒé‡

### 6.1 heparin cofactor 2 deficiencyï¼ˆè­‰æ“šç­‰ç´š: L5ï¼‰

#### è‡¨åºŠå®šç¾©

| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| ç–¾ç—…å…¨å | Heparin cofactor 2 deficiency | |
| ICD-10 | [Data Gap] | WHO |
| è¨ºæ–·æº–å‰‡ | [Data Gap] | [Data Gap] |
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | |
| æ’é™¤æ¢ä»¶ | [Data Gap] | |
| ç¾è¡Œæ¨™æº–æ²»ç™‚ (SoC) | [Data Gap] | [Data Gap] |
| Unmet medical need | [Data Gap] | |
| ä¸»è¦ç™‚æ•ˆæŒ‡æ¨™ | [Data Gap] | |
| ç™‚æ•ˆè©•ä¼°æ™‚é–“é» | [Data Gap] | |

#### è—¥å¸«ç«‹å ´èˆ‡ç†ç”±

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å¸«ç«‹å ´ | æš«ä¸å»ºè­° |
| æ±ºç­–çµè«– | Hold |
| å»ºè­°åŠ‘å‹ | Pending |
| é—œéµæ”¯æŒè­‰æ“š | [Data Gap] |
| é—œéµç¼ºå£ | æ©Ÿè½‰ä¸æ˜ |
| ç«‹å ´è®Šæ›´æ¢ä»¶ | è£œé½Šæ©Ÿè½‰ç ”ç©¶è³‡æ–™ |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°
> **è­‰æ“šç­‰ç´š**ï¼šL5
> **è­‰æ“šé¡å‹**ï¼šåƒ…æ¨¡å‹é æ¸¬

##### å¯å¤–æ¨ç†ç”±

| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | ä¸æ˜ç¢º | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥è³‡æ–™æ”¯æŒ | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | ç„¡è³‡æ–™æ”¯æŒ | å¼± |

##### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºè‡¨åºŠåŸ·è¡Œä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……æ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

---

### 6.2 factor 5 excess with spontaneous thrombosis âš ï¸ åƒ…æ¨¡å‹é æ¸¬

> **è—¥å¸«ç«‹å ´ï¼šæš«ä¸å»ºè­°** â€” è­‰æ“šç­‰ç´š L5ï¼Œç„¡ç›´æ¥è‡¨åºŠè­‰æ“šæ”¯æŒ
> **æ±ºç­–çµè«–ï¼šHold**

| é …ç›® | å…§å®¹ |
|------|------|
| TxGNN åˆ†æ•¸ | 99.84% |
| æ©Ÿè½‰é—œè¯ | ä¸æ˜ç¢º |
| é—œéµç¼ºå£ | ç¼ºä¹è‡¨åºŠè©¦é©—ã€æ©Ÿè½‰ç ”ç©¶ã€å®‰å…¨æ€§è³‡æ–™ |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°
> **è­‰æ“šç­‰ç´š**ï¼šL5
> **è­‰æ“šé¡å‹**ï¼šåƒ…æ¨¡å‹é æ¸¬

##### å¯å¤–æ¨ç†ç”±

| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | ä¸æ˜ç¢º | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥è³‡æ–™æ”¯æŒ | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | ç„¡è³‡æ–™æ”¯æŒ | å¼± |

##### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºè‡¨åºŠåŸ·è¡Œä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……æ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

**è‹¥è¦è®Šæ›´ç«‹å ´éœ€è£œé½Š**ï¼š
- [ ] è‡³å°‘ä¸€é …è§€å¯Ÿæ€§ç ”ç©¶
- [ ] æ©Ÿè½‰åˆç†æ€§è«–è­‰
- [ ] ç›®æ¨™æ—ç¾¤å®‰å…¨æ€§è³‡æ–™

---

### 6.3 antithrombin deficiency type 2 âš ï¸ åƒ…æ¨¡å‹é æ¸¬

> **è—¥å¸«ç«‹å ´ï¼šæš«ä¸å»ºè­°** â€” è­‰æ“šç­‰ç´š L5ï¼Œç„¡ç›´æ¥è‡¨åºŠè­‰æ“šæ”¯æŒ
> **æ±ºç­–çµè«–ï¼šHold**

| é …ç›® | å…§å®¹ |
|------|------|
| TxGNN åˆ†æ•¸ | 99.84% |
| æ©Ÿè½‰é—œè¯ | ä¸æ˜ç¢º |
| é—œéµç¼ºå£ | ç¼ºä¹è‡¨åºŠè©¦é©—ã€æ©Ÿè½‰ç ”ç©¶ã€å®‰å…¨æ€§è³‡æ–™ |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°
> **è­‰æ“šç­‰ç´š**ï¼šL5
> **è­‰æ“šé¡å‹**ï¼šåƒ…æ¨¡å‹é æ¸¬

##### å¯å¤–æ¨ç†ç”±

| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | ä¸æ˜ç¢º | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥è³‡æ–™æ”¯æŒ | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | ç„¡è³‡æ–™æ”¯æŒ | å¼± |

##### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºè‡¨åºŠåŸ·è¡Œä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……æ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

**è‹¥è¦è®Šæ›´ç«‹å ´éœ€è£œé½Š**ï¼š
- [ ] è‡³å°‘ä¸€é …è§€å¯Ÿæ€§ç ”ç©¶
- [ ] æ©Ÿè½‰åˆç†æ€§è«–è­‰
- [ ] ç›®æ¨™æ—ç¾¤å®‰å…¨æ€§è³‡æ–™

---

## 7. Guardrailsï¼ˆè‹¥æ±ºç­–ç‚º Proceed with Guardrailsï¼‰

ï¼ˆä¸é©ç”¨æ–¼æœ¬æ¡ˆä¾‹ï¼‰

---

## 8. Monitoring & Follow-up Workflow

### 8.1 Baseline Monitoringï¼ˆä½¿ç”¨å‰ï¼‰

#### å£æœåŠ‘å‹

| é …ç›® | å¿…è¦æ€§ | é‡æ¸¬æ–¹æ³• | åˆ¤è®€æ¨™æº– |
|-----|-------|---------|---------|
| CBC w/ diff | å¿…è¦ | æŠ½è¡€ | ANC â‰¥ 1,500, Plt â‰¥ 100,000 |
| LFT | å¿…è¦ | æŠ½è¡€ | ALT/AST â‰¤ 2Ã— ULN |
| RFT | å¿…è¦ | æŠ½è¡€ | eGFR â‰¥ 30 mL/min |
| ECG | è¦–æƒ…æ³ | 12-lead | QTc < 470 ms |

---

## 9. Evidence Summary

### 9.1 è­‰æ“šç­‰ç´šåˆ†å¸ƒ

| ç­‰ç´š | é©æ‡‰ç—‡æ•¸ | è‡¨åºŠæ„ç¾© |
|-----|---------|---------|
| L1 | 0 | å¤šå€‹ RCT/ç³»çµ±æ€§å›é¡§ â€” å¯æ”¯æŒè‡¨åºŠä½¿ç”¨ |
| L2 | 0 | å–®ä¸€ RCT â€” å¯è€ƒæ…®ä½¿ç”¨ |
| L3 | 0 | è§€å¯Ÿæ€§ç ”ç©¶ â€” å¾…è£œä»¶å¾Œè©•ä¼° |
| L4 | 0 | å‰è‡¨åºŠ/æ©Ÿè½‰ â€” æš«ä¸å»ºè­° |
| L5 | 3 | åƒ…æ¨¡å‹é æ¸¬ â€” æš«ä¸å»ºè­° |

### 9.2 Limitations
- ç¼ºä¹ç›´æ¥è‡¨åºŠè©¦é©—æ”¯æŒ
- æ©Ÿè½‰ä¸æ˜ç¢º

---

## 10. è£œä»¶è¿½è¹¤è¡¨

| # | ç¼ºå£ | é˜»æ–·æ€§ | è³‡æ–™ä¾†æº | è² è²¬äºº | æˆªæ­¢æ—¥ | ç‹€æ…‹ | å½±éŸ¿ç« ç¯€ |
|---|-----|-------|---------|-------|-------|------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | ğŸ›‘ | DrugBank | å¾…æŒ‡å®š | å¾…å®š | â³ | Â§5 |

---

## é™„éŒ„ï¼šè³‡æ–™æ”¶é›†æ—¥èªŒ

| # | è³‡æ–™ä¾†æº | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | çµæœ | åŸå§‹çµæœé€£çµ |
|---|---------|---------|---------|------|-------------|
| 1 | TFDA | 2026-02-09 | {"drug": "warfarin"} | 20 | [snapshot] |
| 2 | DDI | 2026-02-09 | {"drug": "warfarin"} | 865 | [snapshot] |
| 3 | DrugBank | 2026-02-09 | {"drug": "warfarin"} | 1 | [snapshot] |
| 4 | TFDA ä»¿å–® | 2026-02-09 | {"drug": "warfarin"} | 1 | [snapshot] |
| 5 | ClinicalTrials.gov | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 0 | [snapshot] |

---

## æ–‡ä»¶ç‰ˆæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| æ–‡ä»¶ç‰ˆæœ¬ | v1.0 |
| ç”¢ç”Ÿæ—¥æœŸ | 2026-02-09 |
| è³‡æ–™æˆªæ­¢æ—¥ | 2026-02-09 |
| Evidence Pack ç‰ˆæœ¬ | warfarin_v4_2026-02-09.json |

---

<div id="sponsor">

## è´ŠåŠ©å•†å ±å‘Š

</div>

# Sponsor Notes â€” Warfarin è€è—¥æ–°ç”¨é–‹ç™¼è©•ä¼°

---

## âš ï¸ è³‡æ–™å®Œæ•´æ€§èˆ‡å¯ç”¨æ€§è²æ˜

**æ–‡ä»¶ç”¢å‡ºæ—¥æœŸ**ï¼š2026-02-09
**æ±ºç­–éšæ®µ**ï¼šS0ï¼ˆåˆæ­¥è©•ä¼°ï¼‰
**ç›®å‰æ±ºç­–**ï¼šHold

### æœ¬æ–‡ä»¶å¯æ”¯æŒçš„æ±ºç­–

| å¯æ”¯æŒ | ä¸å¯æ”¯æŒ |
|-------|---------|
| Research Question only | é–‹ç™¼å»ºè­°ï¼ˆGo/Conditional Goï¼‰ |

### é˜»æ–·æ€§ç¼ºå£æ‘˜è¦

| # | ç¼ºå£é …ç›® | æ¨è«–é™åˆ¶ | è§£é–æ¢ä»¶ |
|---|---------|---------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | å½±éŸ¿æ©Ÿè½‰é—œè¯æ€§åˆ†æ | éœ€æŸ¥è©¢ DrugBank API |

### ä¿å®ˆå‡è¨­æ‘˜è¦

| # | å‡è¨­ | ä¾æ“š | é™åˆ¶ | è§¸ç™¼æ¢ä»¶ |
|---|------|------|------|---------|
| 1 | æš«ç„¡ä¿å®ˆå‡è¨­ | - | - | - |

---

> âš ï¸ **é‡è¦è²æ˜**
>
> 1. æœ¬æ–‡ä»¶åŒ…å«ã€Œå·²è­‰å¯¦è³‡è¨Šã€èˆ‡ã€Œå‡è¨­/æ¨è«–ã€ã€‚
> 2. å‡¡æ¨™ç¤ºç‚º **Blocking Data Gap** ä¹‹é …ç›®æœªè§£é™¤å‰ï¼Œæœ¬æ–‡ä»¶ **ä¸æä¾›**ï¼š
>    - é–‹ç™¼å»ºè­°ï¼ˆGo/Conditional Goï¼‰
>    - æ’é™¤æ¢ä»¶å®šç¨¿
>    - è©¦é©—è¨­è¨ˆä¾æ“š
> 3. è‹¥å¾ŒçºŒå–å¾—æ–°è³‡æ–™ï¼Œå°‡ä¾è§£é–æ¢ä»¶æ›´æ–°é¢¨éšªåˆ†ç´šèˆ‡æ±ºç­–ã€‚

---

## 0. è—¥ç‰©å†åˆ©ç”¨ç¸½è¦½

### è³‡æ–™ä¾†æºç¨½æ ¸æ¡†ï¼ˆData Provenanceï¼‰

| è³‡æ–™ä¾†æº | ç‹€æ…‹ | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | ç­†æ•¸/å‚™è¨» | å°æ±ºç­–çš„å½±éŸ¿ |
|---------|------|---------|---------|----------|-------------|
| TFDA è¨±å¯è­‰ | âœ… | 2026-02-09 | {"drug": "warfarin"} | 20 | å·²ä¸Šå¸‚ |
| TFDA ä»¿å–® | âœ… | 2026-02-09 | {"drug": "warfarin"} | 1 | å½±éŸ¿è©•ä¼° |
| DDI è³‡æ–™åº« (Unified DDI) | âœ… | 2026-02-09 | {"drug": "warfarin"} | 865 | å½±éŸ¿å®‰å…¨æ€§è©•ä¼° |
| DrugBank (MOA) | âœ… | 2026-02-09 | {"drug": "warfarin"} | 1 | å½±éŸ¿æ©Ÿè½‰é—œè¯æ€§åˆ†æ |
| ClinicalTrials.gov | âœ… (ç„¡çµæœ) | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 0 | ç„¡ç›´æ¥è‡¨åºŠè©¦é©—æ”¯æŒ |
| PubMed | âœ… | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 5 | æ–‡ç»æ”¯æŒæœ‰é™ |

### è—¥ç‰©åŸºæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è—¥ç‰©åç¨± | Warfarin | |
| DrugBank ID | DB00682 | |
| **åŸæ ¸å‡†é©æ‡‰ç—‡** | æŠ—å‡è¡€åŠ‘ã€è¡€ç®¡æ “å¡ç­‰ | [ä¾†æºï¼šTFDA] |
| **åŸä½œç”¨æ©Ÿè½‰ (MOA)** | [Data Gap] | [ä¾†æºï¼šDrugBank] |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | å·²ä¸Šå¸‚ | TFDA |

### è¨±å¯è­‰è©³ç´°è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | æ¿ƒåº¦ | è£½é€ å»  | ä»¿å–®ç‰ˆæœ¬ |
|---------|---------|------|------|-------|---------|
| å…§è¡›è—¥è¼¸å­—ç¬¬002494è™Ÿ | æ´»ç¦å¯§éˆ‰ç‰‡ | éŒ åŠ‘ | - | é›„æ†è¡Œè‚¡ä»½æœ‰é™å…¬å¸ | - |
| å…§è¡›è—¥è¼¸å­—ç¬¬002938è™Ÿ | å®‰æ±å‘½ï¼ï¼« | éŒ åŠ‘ | - | å‰ç™¼ä¼æ¥­è‚¡ä»½æœ‰é™å…¬å¸ | - |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026478è™Ÿ | è‹¯ç”²é¦™è±†é†‡éˆ‰ç± æ™¶ | ï¼ˆç²‰ï¼‰ | - | æ–°é›™éš†ç”ŸæŠ€è‚¡ä»½æœ‰é™å…¬å¸ | - |
| è¡›ç½²è—¥è£½å­—ç¬¬050068è™Ÿ | æ¬£æœå¯§ éŒ  1 æ¯«å…‹ | éŒ åŠ‘ | 1 æ¯«å…‹ | å¥å–¬ä¿¡å…ƒé†«è—¥ç”ŸæŠ€è‚¡ä»½æœ‰é™å…¬å¸ | - |

### å¯ç”¨åŠ‘å‹ï¼ˆæŒ‰çµ¦è—¥é€”å¾‘ï¼‰

| çµ¦è—¥é€”å¾‘ | åŠ‘å‹ | é–‹ç™¼é–€æª» |
|---------|------|---------|
| å£æœ | éŒ åŠ‘ | ä¸­é«˜ |
| å…¶ä»– | ï¼ˆç²‰ï¼‰ | ä¸­é«˜ |

### é æ¸¬æ–°é©æ‡‰ç—‡ç¸½è¦½

| æ’å | é æ¸¬é©æ‡‰ç—‡ | TxGNN åˆ†æ•¸ | è­‰æ“šç­‰ç´š | è‡¨åºŠè©¦é©— | å»ºè­°åŠ‘å‹ | é–‹ç™¼å»ºè­° | æ±ºç­–çµè«– | é˜»æ–·å› ç´  |
|------|-----------|-----------|---------|---------|---------|---------|---------|---------|
| 1 | heparin cofactor 2 deficiency | 99.87% | L5 | 0 é … | å£æœ | Hold | Hold | æ©Ÿè½‰ä¸æ˜ |
| 2 | factor 5 excess with spontaneous thrombosis | 99.84% | L5 | 0 é … | å£æœ | Hold | Hold | æ©Ÿè½‰ä¸æ˜ |
| 3 | antithrombin deficiency type 2 | 99.84% | L5 | 0 é … | å£æœ | Hold | Hold | æ©Ÿè½‰ä¸æ˜ |

**æ•´é«”é–‹ç™¼å»ºè­°**ï¼šç›®å‰æ‰€æœ‰é æ¸¬é©æ‡‰ç—‡å‡å› æ©Ÿè½‰ä¸æ˜ç¢ºå’Œç¼ºä¹è‡¨åºŠè©¦é©—æ”¯æŒè€Œå»ºè­° Holdã€‚

---

## 1. Executive Brief (â‰¤1 page)

### é–‹ç™¼æ±ºç­–ç¸½è¦½

| é©æ‡‰ç—‡ | é–‹ç™¼å»ºè­° | æ±ºç­–çµè«– | æ±ºç­–éšæ®µ | é—œéµæ”¯æŒ | é—œéµç¼ºå£ | Pharmacist å°æ‡‰ç«‹å ´ |
|-------|---------|---------|---------|---------|---------|-------------------|
| heparin cofactor 2 deficiency | Hold | Hold | S0 | æ–‡ç»æ”¯æŒæœ‰é™ | æ©Ÿè½‰ä¸æ˜ | æš«ä¸å»ºè­° |
| factor 5 excess with spontaneous thrombosis | Hold | Hold | S0 | ç„¡æ–‡ç»æ”¯æŒ | æ©Ÿè½‰ä¸æ˜ | æš«ä¸å»ºè­° |
| antithrombin deficiency type 2 | Hold | Hold | S0 | æ–‡ç»æ”¯æŒæœ‰é™ | æ©Ÿè½‰ä¸æ˜ | æš«ä¸å»ºè­° |

### æ•´é«”æ±ºç­–å»ºè­°
- **æœ€å„ªå…ˆé–‹ç™¼**ï¼šç„¡
- **æ¬¡å„ªå…ˆé–‹ç™¼**ï¼šç„¡
- **Hold**ï¼šæ‰€æœ‰é©æ‡‰ç—‡ â€” å¾…æ©Ÿè½‰æ˜ç¢ºå¾Œå¯å‡ç´š
- **No-Go**ï¼šç„¡

### Top 3 Key Points
1. Warfarin å·²åœ¨å°ç£ä¸Šå¸‚ï¼Œä¸»è¦ç”¨æ–¼æŠ—å‡è¡€ã€‚[ä¾†æºï¼šTFDA]
2. æ‰€æœ‰é æ¸¬é©æ‡‰ç—‡çš„æ©Ÿè½‰é—œè¯æ€§ä¸æ˜ç¢ºã€‚[ä¾†æºï¼šDrugBank]
3. æ–‡ç»æ”¯æŒæœ‰é™ï¼Œç„¡ç›¸é—œè‡¨åºŠè©¦é©—ã€‚[ä¾†æºï¼šPubMed]

### Top Risks & Mitigation

| é¢¨éšªé¡å‹ | æè¿° | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|---------|------|-------|---------|
| è­‰æ“š | æ©Ÿè½‰ä¸æ˜ç¢º | é«˜ | é€²ä¸€æ­¥ç ”ç©¶æ©Ÿè½‰ |
| å®‰å…¨æ€§ | DDI å¤šé” 865 ç¨® | ä¸­ | å¼·åŒ– DDI ç›£æ§ |
| æ³•è¦ | ç„¡æ³•ç›´æ¥æ”¯æŒæ–°é©æ‡‰ç—‡ | é«˜ | éœ€è£œå……æ©Ÿè½‰ç ”ç©¶ |

### Next Step MVPï¼ˆè‹¥ç‚º Go/Conditional Goï¼‰
- ç„¡

---

## 2. è—¥ç‰©å±¤ç´šè³‡è¨Š

### 2.1 Taiwan Regulatory Snapshot
- **TFDA ä¸Šå¸‚ç‹€æ…‹**ï¼šå·²ä¸Šå¸‚ [ä¾†æºï¼šTFDA]
- **æ ¸å‡†é©æ‡‰ç—‡**ï¼šæŠ—å‡è¡€åŠ‘ã€è¡€ç®¡æ “å¡ç­‰ [ä¾†æºï¼šTFDA]
- **è¨±å¯è­‰è™Ÿ**ï¼šå…§è¡›è—¥è¼¸å­—ç¬¬002494è™Ÿã€å…§è¡›è—¥è¼¸å­—ç¬¬002938è™Ÿç­‰

**Label Constraints / Warnings**ï¼š
[Data Gap] å½±éŸ¿è©•ä¼° [ä¾†æºï¼šTFDA]

### 2.2 Safety Profile â€” æŒ‰åŠ‘å‹åˆ†åˆ—

#### å£æœ/å…¨èº«æ€§åŠ‘å‹

| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| Key warnings | [Data Gap] | [ä¾†æºï¼šTFDA] |
| å¸¸è¦‹ ADR | [Data Gap] | [ä¾†æºï¼šTFDA] |
| é–‹ç™¼é¢¨éšª | ä¸­-é«˜ | |

### 2.3 DDI æŸ¥æ ¸çµæœ

**æŸ¥è©¢ç‹€æ…‹**ï¼šâœ… å·²å®Œæˆ

**å·²åŸ·è¡Œçš„æŸ¥è©¢**ï¼š
1. Unified DDI è³‡æ–™åº«ï¼ˆDDInter + Guide to PHARMACOLOGYï¼‰ï¼šæŸ¥è©¢æˆåŠŸï¼Œ865 ç­†ç›¸é—œ DDI
2. DrugBank Interactionsï¼šæŸ¥è©¢æˆåŠŸ

**æ˜ç¢ºé™³è¿°**ï¼š
> æœ¬å ±å‘Š **å·²å®Œæˆ** DDI æ­£å¼æŸ¥æ ¸ã€‚
> ä¸Šè¿°æŸ¥è©¢çµæœ **è¶³ä»¥** æ”¯æŒã€Œå­˜åœ¨å¤šé … DDI éœ€ç›£æ§ã€çš„çµè«–ã€‚
> æ­¤ç‚º **Non-blocking Data Gap**ï¼Œå°é–‹ç™¼å»ºè­°çš„å½±éŸ¿ï¼šéœ€å¼·åŒ–ç›£æ§ã€‚

### 2.4 åŸé©æ‡‰ç—‡ä½œç”¨æ©Ÿè½‰
- **MOA**ï¼š[Data Gap] [ä¾†æºï¼šDrugBank]
- **èˆ‡æ–°é©æ‡‰ç—‡ç›¸é—œçš„è—¥ç†ç‰¹æ€§**ï¼šæœªæ˜ç¢º [ä¾†æºï¼šDrugBank]

---

## 3. Data Gaps å®Œæ•´è¨˜éŒ„

### Data Gap #1 â€” ä½œç”¨æ©Ÿè½‰ (MOA)ï¼ˆğŸ›‘ Blockingï¼‰

| æ¬„ä½ | å…§å®¹ |
|------|------|
| **ç¼ºå£é …ç›®** | ä½œç”¨æ©Ÿè½‰ (MOA) |
| **å·²å®Œæˆæª¢ç´¢è¡Œå‹•** | |
| | â€¢ å®˜æ–¹æ¨™ç±¤/ä¸»ç®¡æ©Ÿé—œè³‡æ–™ï¼ˆTFDA/FDA/EMA/PMDAï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ æ¬Šå¨è—¥å­¸è³‡æ–™åº«ï¼ˆDDInter/Guide to PHARMACOLOGY/DrugBankï¼‰ï¼šæŸ¥è©¢æˆåŠŸï¼Œæœªæ˜ç¢º |
| | â€¢ åŒå„•å¯©æŸ¥æ–‡ç»ï¼ˆPubMed/æœŸåˆŠï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ è©¦é©—ç™»éŒ„ï¼ˆClinicalTrials.govï¼‰ï¼šæœªæ‰¾åˆ° |
| **æª¢ç´¢çµæœ** | æœªæ‰¾åˆ° |
| **æ¨è«–é™åˆ¶ï¼ˆä¸èƒ½åšï¼‰** | ç„¡æ³•é€²è¡Œæ©Ÿè½‰é—œè¯æ€§åˆ†æ |
| **é¢¨éšªè™•ç½®ï¼ˆæ±ºç­–ï¼‰** | Hold |
| **è§£é–æ¢ä»¶** | éœ€è¦æŸ¥è©¢ DrugBank API ä»¥ç²å¾—ä½œç”¨æ©Ÿè½‰è³‡æ–™ |

---

## 4. å„é©æ‡‰ç—‡è©³ç´°è©•ä¼°

### 4.1 Heparin cofactor 2 deficiency

#### åŸºæœ¬è³‡è¨Šèˆ‡æ±ºç­–

| é …ç›® | å…§å®¹ |
|------|------|
| ç–¾ç—…åç¨± | Heparin cofactor 2 deficiency |
| ICD-10 | [Data Gap] |
| TxGNN åˆ†æ•¸ | 99.87% |
| è­‰æ“šç­‰ç´š | L5 |
| å»ºè­°åŠ‘å‹ | å£æœ |
| **é–‹ç™¼å»ºè­°** | Hold |
| **æ±ºç­–çµè«–** | Hold |
| **Pharmacist å°æ‡‰** | æš«ä¸å»ºè­° |
| æ±ºç­–éšæ®µ | S0 |
| é˜»æ–·å‡ç´šå› ç´  | æ©Ÿè½‰ä¸æ˜ |

#### è‡¨åºŠå®šç¾©

| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è¨ºæ–·æº–å‰‡ | [Data Gap] | - |
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | - |
| æ’é™¤æ¢ä»¶ | [Data Gap] | - |
| ç¾è¡Œ SoC | [Data Gap] | - |
| Unmet need | [Data Gap] | - |
| æµè¡Œç—…å­¸ | [Data Gap] | - |

#### æ©Ÿè½‰é—œè¯æ€§åˆ†æ

| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| åŸé©æ‡‰ç—‡æ©Ÿè½‰ | [Data Gap] | [ä¾†æºï¼šDrugBank] |
| æ–°é©æ‡‰ç—‡ç—…ç† | [Data Gap] | [ä¾†æºï¼šPubMed] |
| æ©Ÿè½‰é—œè¯ | ä¸æ˜ç¢º | [ä¾†æºï¼šDrugBank] |
| ç›¸ä¼¼åº¦ | ä½ | |
| é¡ä¼¼å†åˆ©ç”¨å…ˆä¾‹ | ç„¡ | [ä¾†æºï¼šDrugBank] |

#### è‡¨åºŠè©¦é©—ï¼ˆæ¨™è¨»ç›¸é—œæ€§ï¼‰

| è©¦é©—ç·¨è™Ÿ | ç›¸é—œæ€§ | éšæ®µ | ç‹€æ…‹ | N | çµæœæ‘˜è¦ |
|---------|-------|-----|------|---|---------|
| ç„¡ | - | - | - | - | - |

#### æ–‡ç»è­‰æ“šï¼ˆæ¨™è¨»æ”¯æ’é¢å‘ï¼‰

| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | æ”¯æ’é¢å‘ | ä¸»è¦ç™¼ç¾ | é™åˆ¶ |
|------|-----|---------|---------|---------|------|
| 11177584 | 2001 | Review | â˜ç™‚æ•ˆ â˜‘æ©Ÿè½‰ â˜å®‰å…¨æ€§ â˜æ—ç¾¤ | Thrombosis in HIV | ç›¸é—œæ€§å¾…ç¢ºèª |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°ï¼ˆL4/L5 å¿…å¡«ï¼‰
### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°

**è­‰æ“šç­‰ç´š**ï¼šL5
**è­‰æ“šé¡å‹**ï¼šæ–‡ç»å›é¡§èˆ‡å€‹æ¡ˆå ±å‘Š

#### å¯å¤–æ¨ç†ç”±

| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | ç¼ºä¹æ©Ÿè½‰æ”¯æŒ | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥è­‰æ“š | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | å£æœåŠ‘å‹å¯è¡Œ | ä¸­ |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºé–‹ç™¼æ±ºç­–ä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……æ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

---

### 4.2 Factor 5 excess with spontaneous thrombosis

| é …ç›® | å…§å®¹ |
|------|------|
| TxGNN åˆ†æ•¸ | 99.84% |
| è­‰æ“šç­‰ç´š | L5 |
| **é–‹ç™¼å»ºè­°** | Hold |
| **æ±ºç­–çµè«–** | Hold |
| **Pharmacist å°æ‡‰** | æš«ä¸å»ºè­° |

**é˜»æ–·/Hold åŸå› **ï¼šæ©Ÿè½‰ä¸æ˜ç¢ºï¼Œç„¡æ–‡ç»æ”¯æŒã€‚

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°
### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°

**è­‰æ“šç­‰ç´š**ï¼šL5
**è­‰æ“šé¡å‹**ï¼šæ¨¡å‹é æ¸¬

#### å¯å¤–æ¨ç†ç”±

| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | ç¼ºä¹æ©Ÿè½‰æ”¯æŒ | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥è­‰æ“š | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | å£æœåŠ‘å‹å¯è¡Œ | ä¸­ |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºé–‹ç™¼æ±ºç­–ä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……æ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

---

### 4.3 Antithrombin deficiency type 2

| é …ç›® | å…§å®¹ |
|------|------|
| TxGNN åˆ†æ•¸ | 99.84% |
| è­‰æ“šç­‰ç´š | L5 |
| **é–‹ç™¼å»ºè­°** | Hold |
| **æ±ºç­–çµè«–** | Hold |
| **Pharmacist å°æ‡‰** | æš«ä¸å»ºè­° |

**é˜»æ–·/Hold åŸå› **ï¼šæ©Ÿè½‰ä¸æ˜ç¢ºï¼Œæ–‡ç»æ”¯æŒæœ‰é™ã€‚

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°
### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°

**è­‰æ“šç­‰ç´š**ï¼šL5
**è­‰æ“šé¡å‹**ï¼šå€‹æ¡ˆå ±å‘Š

#### å¯å¤–æ¨ç†ç”±

| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | ç¼ºä¹æ©Ÿè½‰æ”¯æŒ | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥è­‰æ“š | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | å£æœåŠ‘å‹å¯è¡Œ | ä¸­ |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºé–‹ç™¼æ±ºç­–ä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……æ©Ÿè½‰ç ”ç©¶å¾Œæ‰èƒ½å‡ç´š

---

## 5. é©æ‡‰ç—‡æ¯”è¼ƒèˆ‡å„ªå…ˆé †åº

### 5.1 è­‰æ“šå¼·åº¦æ¯”è¼ƒ

| é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | RCT | è§€å¯Ÿæ€§ | å‰è‡¨åºŠ | å¼·åº¦è©•åˆ† |
|-------|---------|-----|-------|-------|---------|
| heparin cofactor 2 deficiency | L5 | 0 | 0 | 0 | ä½ |
| factor 5 excess with spontaneous thrombosis | L5 | 0 | 0 | 0 | ä½ |
| antithrombin deficiency type 2 | L5 | 0 | 0 | 0 | ä½ |

### 5.2 é–‹ç™¼å¯è¡Œæ€§æ¯”è¼ƒ

| é©æ‡‰ç—‡ | åŠ‘å‹ | åŠ‘å‹é¢¨éšª | å®‰å…¨æ€§é¢¨éšª | DDI é¢¨éšª | æ³•è¦è·¯å¾‘ | å¯è¡Œæ€§ |
|-------|-----|---------|-----------|---------|---------|-------|
| heparin cofactor 2 deficiency | å£æœ | ä¸­é«˜ | ä¸­ | ä¸­ | ä¸æ˜ | ä½ |
| factor 5 excess with spontaneous thrombosis | å£æœ | ä¸­é«˜ | ä¸­ | ä¸­ | ä¸æ˜ | ä½ |
| antithrombin deficiency type 2 | å£æœ | ä¸­é«˜ | ä¸­ | ä¸­ | ä¸æ˜ | ä½ |

### 5.3 å„ªå…ˆé–‹ç™¼é †åº
1. **heparin cofactor 2 deficiency**ï¼šæ©Ÿè½‰ä¸æ˜ï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶ã€‚
2. **factor 5 excess with spontaneous thrombosis**ï¼šç„¡æ–‡ç»æ”¯æŒï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶ã€‚
3. **antithrombin deficiency type 2**ï¼šæ–‡ç»æ”¯æŒæœ‰é™ï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶ã€‚

---

## 6. Risk Register

### 6.1 Evidence Risk

| é©æ‡‰ç—‡ | é¢¨éšª | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-------|-----|-------|---------|
| heparin cofactor 2 deficiency | æ©Ÿè½‰ä¸æ˜ | é«˜ | é€²ä¸€æ­¥ç ”ç©¶æ©Ÿè½‰ |

### 6.2 Safety Risk

| é¢¨éšª | å½±éŸ¿é©æ‡‰ç—‡ | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-----|-----------|-------|---------|
| DDI å¤šé … | æ‰€æœ‰é©æ‡‰ç—‡ | ä¸­ | å¼·åŒ–ç›£æ§ |

### 6.3 Regulatory/Operational Risk

| é¢¨éšª | æè¿° | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-----|------|-------|---------|
| æ³•è¦ | ç„¡æ³•æ”¯æŒæ–°é©æ‡‰ç—‡ | é«˜ | éœ€è£œå……æ©Ÿè½‰ç ”ç©¶ |

---

## 7. è£œä»¶è¿½è¹¤è¡¨

| # | ç¼ºå£ | é˜»æ–·æ€§ | è³‡æ–™ä¾†æº | è² è²¬äºº | æˆªæ­¢æ—¥ | ç‹€æ…‹ | å½±éŸ¿ç« ç¯€ | è£œä»¶å¾Œå¯é”å»ºè­° |
|---|-----|-------|---------|-------|-------|------|---------|--------------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | ğŸ›‘ | DrugBank API | - | - | â³ | Â§2.4 | Hold |

---

## 8. è£œä»¶å¾Œæ±ºç­–å‡ç´šè·¯å¾‘

```
ç•¶å‰ç‹€æ…‹ï¼šS0 â†’ æœ€é«˜å»ºè­°ï¼šHold

è£œä»¶è·¯å¾‘ 1ï¼šè£œé½Š MOA è³‡æ–™
  â†’ å¯é”ï¼šS1 â†’ å‡ç´šè‡³ï¼šConditional Go

è£œä»¶è·¯å¾‘ 2ï¼šè£œé½Š MOA + æ–‡ç»æ”¯æŒ
  â†’ å¯é”ï¼šS2 â†’ å‡ç´šè‡³ï¼šGo
```

---

## é™„éŒ„ï¼šè³‡æ–™æ”¶é›†æ—¥èªŒ

| # | è³‡æ–™ä¾†æº | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | çµæœ | åŸå§‹çµæœé€£çµ |
|---|---------|---------|---------|------|-------------|
| 1 | TFDA | 2026-02-09 | {"drug": "warfarin"} | 20 | [snapshot] |
| 2 | DDI | 2026-02-09 | {"drug": "warfarin"} | 865 | [snapshot] |
| 3 | DrugBank | 2026-02-09 | {"drug": "warfarin"} | 1 | [snapshot] |
| 4 | ClinicalTrials.gov | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 0 | [snapshot] |
| 5 | PubMed | 2026-02-09 | {"drug": "warfarin", "disease": "heparin cofactor 2 deficiency"} | 5 | [snapshot] |

---

## æ–‡ä»¶ç‰ˆæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| æ–‡ä»¶ç‰ˆæœ¬ | v1.0 |
| ç”¢ç”Ÿæ—¥æœŸ | 2026-02-09 |
| è³‡æ–™æˆªæ­¢æ—¥ | 2026-02-09 |
| Evidence Pack ç‰ˆæœ¬ | TW-DB00682-multi_v4_2026-02-09.json |
